MORE►
Breyer Capital
Cloned by Viagen in 2023 from cells frozen for more than 40 years, “Ollie,” a Przewalski’s horse foal shown here at five days old, marks another milestone in using biotechnology to help restore threatened animal populations. [Photo: Elizabeth Arellano Photography/Viagen]
Dallas Decacorn Colossal Buys Viagen, a Texas Pioneer in Animal Cloning
by Quincy Preston | Nov 4, 2025
The de-extinction startup is adding more than two decades of commercial cloning expertise to its portfolio with its first acquisition.
Days before the announcement, CEO Ben Lamm laid out his playbook at Venture Dallas 2025: run toward critics, treat promises to middle-America classrooms as seriously as commitments to investors—and spin out businesses worth more than $100 million.
by David Seeley |
Jan 31, 2023
Colossal says its efforts could help boost "the U.S. high-tech advantage." Its gene editing technologies "will make waves across sectors—in agriculture with new biofuels and preserving biodiversity, as well as in human health through improved gene therapy and vaccine development," the company said.
MORE►
by Quincy Preston and David Seeley |
Mar 9, 2022
Colossal launched last September with a plan to "de-extinct" the woolly mammoth by using CRISPR genetic engineering to create a mammoth-elephant hybrid.
With a total raise of $75 million to date, the startup aims to
have its first set of mammoth-elephant hybrid calves "in 4 to 6 years," co-founder and CEO Ben Lamm told us. But Colossal's goals extend much further—with the potential "to advance human health, enhance food production, reduce environmental impact, and optimize animal health and welfare."
MORE►
